Last spring, EQL Pharma announced an expansion of the product line to include an antigen covid-19 self-test (under the Boson brand) for its own use, and since October it has also had a saliva-based self-test (under the Alltest brand) available.

During the year, the company successfully delivered these covid-19 antigen self-tests both in Sweden and internationally.

The company has now received a major individual order for an antigen self-test with a sales value of approximately SEK 23 million. Revenue is expected to fall during EQL Pharma's fourth financial quarter (January-March).

This disclosure contains information that EQL Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 21-12-2021 13:13 CET.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 - 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

Eql Pharma AB (Publ) briefly
EQL Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.

https://news.cision.com/eql-pharma/r/eql-pharma-receives-sek-23-million-order-for-covid-self-test,c3476649

https://mb.cision.com/Main/11664/3476649/1513218.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English